Turgay Ulas

Prof. Dr. Turgay Ulas

Hamatology andStem Cell Transplantation Unit, University of Health Sciences, Dr. Abdurrahman Yueraslan Ankara Oncology Training and Research Hospital, Ankara, Turkey (Türkiye)
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2013 in European Journal of Radiology
Verified
Journal Article
Closed access
PDF file
HCHasan Cece
Hasan Cece
AEAbdulbasit Ercan
Abdulbasit Ercan
SYSema Yıldız
Sema Yıldız
EKEkrem Karakas
Ekrem Karakas
OKOmer Karakas
Omer Karakas
Turgay UlasTurgay Ulas
Turgay Ulas

1 April 2013 in Revista da Escola de Enfermagem da USP
Verified
Journal Article
Open access
PDF file
Turgay UlasTurgay Ulas
Turgay Ulas
HBHakan Buyukhatipoglu
Hakan Buyukhatipoglu
IKIdris Kirhan
Idris Kirhan
MDMehmet Sinan Dal
Mehmet Sinan Dal
SUSevilay Ulas
Sevilay Ulas
NANurten Aksoy
Nurten Aksoy
The aim of this study was to evaluate the oxidative stress and metabolic activities of nurses working day and night shifts. Intensive care unit (ICU) (n=70) and ordinary service (OS) nurses (n=70) were enrolled in the study. Just before and the end of the shifts, blood samples were obtained to measure the participants' oxidative stress parameters. Metabolic activities were analyzed using the SenseWear Armband. Oxidative stress parameters were increased at the end of the shifts for all OS and ICU nurses compared to the beginning of the shifts. Compared to the OS nurses, the ICU nurses' TAS, TOS, and OSI levels were not significantly different at the end of the day and night shifts. The metabolic activities of the OS and ICU nurses were found to be similar. As a result, the OS and ICU nurses' oxidative stress parameters and metabolic activities were not different, and all of the nurses experienced similar effects from both the day and night shifts.

5 March 2013 in Medicina
Verified
Journal Article
Open access
SYSaban Yalcin
Saban Yalcin
Turgay UlasTurgay Ulas
Turgay Ulas
MEMehmet Eren
Mehmet Eren
HAHarun Aydogan
Harun Aydogan
ACAysun Camuzcuoglu
Aysun Camuzcuoglu
NANurten Aksoy
Nurten Aksoy
Background and Objective. Oxidative stress is believed to play a role in the development of preeclampsia (PE). It is known that an increased cystatin C level is also associated with PE. The aim of this study was to investigate the relationship between oxidative stress parameters and cystatin C levels in patients with severe PE. Material and Methods. Forty-four patients with severe PE and 40 healthy pregnant women were recruited for the study. All study subjects were divided into 2 groups: group 1 (n=44) consisted of patients with severe PE, and group 2 (n=40) included healthy pregnant subjects. Blood samples were obtained from all subjects in order to measure the cystatin C level, total antioxidant status, and total oxidant status. The oxidative stress index was calculated. Results. The group 1 had significantly higher cystatin C, total oxidant status, oxidative stress index levels and lower total antioxidant status level as compared with the group 2 (P=0.001, P<0.001, P<0.001, P=0.036, respectively). The serum cystatin C level was significantly correlated with the oxidative stress index (r=0.609, P<0.001). Conclusions. The present study demonstrated that both oxidative stress and cystatin C levels were increased in patients with PE, and the increased cystatin C levels seem to be a consequence of oxidative stress. Correspondence to

1 May 2012
Verified
Journal Article
Closed access
Turgay UlasTurgay Ulas
Turgay Ulas
HBH Buyukhatipoglu
H Buyukhatipoglu
IKI Kirhan
I Kirhan
MDM S Dal
M S Dal
MEM A Eren
M A Eren
IKI C Kurkcuoglu
I C Kurkcuoglu

4 July 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
TZTugba Zorlu
Tugba Zorlu
MKMerve Apaydin Kayer
Merve Apaydin Kayer
NONazik Okumus
Nazik Okumus
Turgay UlasTurgay Ulas
Turgay Ulas
MDMehmet Sinan Dal
Mehmet Sinan Dal
FAFevzi Altuntas
Fevzi Altuntas
Background: Multiple myeloma (MM) is a heterogeneous plasma cell malignancy with non-specific symptoms and disease heterogeneity at clinical and biological levels. This non-specific set of symptoms, including bone pain, anemia, renal failure, hypercalcemia, and neuropathy, can mislead diagnosis as chronic or benign conditions, resulting in a delay in diagnosis. Timely identification is paramount to prevent organ damage and reduce morbidity. Methods: In this review, we present an overview of recent literature concerning the factors leading to the delayed diagnosis of MM and the impact of delayed diagnosis. This includes factors relevant to physicians and systems, diagnostic processes, primary healthcare services, and laboratory and imaging data access and interpretation. Other emerging technologies to diagnose NCIs include AI-based decision support systems and biomarker-focused strategies. Findings: Delayed diagnosis can lead to presentation at advanced disease stages associated with life-threatening complications and shorter progression-free survival. Patients are often seen by many physicians before they are referred to hematology. Understanding of clinical red flags for MM in primary care is inadequate. Our findings indicate that limited access to diagnostic tests, inconsistent follow-up of MGUS/SMM patients, and a lack of interdepartmental coordination delay the diagnostic process. Conclusions: Multimodal tools for early diagnosis of MM. Educational campaigns to raise awareness of the disease, algorithms dedicated to routine care and novel technologies, including AI and big data analytics, and new biomarkers may serve this purpose, as well as genomic approaches to the premalignant MGUS stage.

30 June 2025 in Hematology Reports
Verified
Journal Article
Open access
PDF file
UHUgur Hatipoglu
Ugur Hatipoglu
Mert SeyhanMert Seyhan
Mert Seyhan
Turgay UlasTurgay Ulas
Turgay Ulas
MDMehmet Sinan Dal
Mehmet Sinan Dal
FAFevzi Altuntaş
Fevzi Altuntaş
Solitary plasmacytoma refers to a neoplastic, clonal proliferation of plasma cells forming a single mass. They are divided based on their origin site; solitary bone plasmacytomas originate from the bones, and extramedullary plasmacytomas represent extraosseous tumors. These are rare tumors but carry a risk of transforming to multiple myeloma; thus, optimal management and meticulous follow-up are needed. Their rarity poses a major challenge in conducting large-scale clinical trials, leaving important gaps in evidence regarding best practices. Newer imaging techniques have improved the quality of staging, management decisions, and outcomes. Radiation still has a significant role in treatment algorithms, and adjuvant chemotherapy is gaining more importance; trials are underway in this area. Follow-up should contain biochemical tests as the proposed response definition criteria. We aimed to review the key studies and guidelines in this paper.